S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?
NASDAQ:HBIO

Harvard Bioscience - HBIO Stock Forecast, Price & News

$2.76
+0.15 (+5.75%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.59
$2.76
50-Day Range
$2.17
$2.86
52-Week Range
$2.10
$7.36
Volume
34,897 shs
Average Volume
181,010 shs
Market Capitalization
$114.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Harvard Bioscience MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
44.9% Upside
$4.00 Price Target
Short Interest
Healthy
0.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
0.22mentions of Harvard Bioscience in the last 14 days
Based on 25 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.03) to $0.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Computer And Technology Sector

260th out of 621 stocks

Analytical Instruments Industry

9th out of 28 stocks

HBIO stock logo

About Harvard Bioscience (NASDAQ:HBIO) Stock

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

HBIO Stock News Headlines

Ledlum's 18 lead Harvard past Tufts 76-59
UMass at Harvard odds, tips and betting trends
See More Headlines
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

HBIO Company Calendar

Last Earnings
11/02/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/14/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
475
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+44.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-290,000.00
Pretax Margin
-6.07%

Debt

Sales & Book Value

Annual Sales
$118.90 million
Cash Flow
$0.40 per share
Book Value
$2.04 per share

Miscellaneous

Free Float
39,075,000
Market Cap
$114.98 million
Optionable
Optionable
Beta
1.70

Key Executives

  • Mr. James W. GreenMr. James W. Green (Age 64)
    Pres, CEO & Chairman
    Comp: $1.02M
  • Mr. Michael A. Rossi (Age 48)
    Chief Financial Officer
    Comp: $478.75k
  • Mr. Kenneth Fletcher Olson (Age 60)
    Exec. Officer
    Comp: $414.31k
  • Mr. David Balcom
    Sr. VP of Operations
  • Ms. Kara Weiner
    Sr. VP of Marketing & Product Management
  • David Sirois
    Director of Corp. Accounting & SEC Reporting













HBIO Stock - Frequently Asked Questions

Should I buy or sell Harvard Bioscience stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HBIO shares.
View HBIO analyst ratings
or view top-rated stocks.

What is Harvard Bioscience's stock price forecast for 2023?

1 Wall Street research analysts have issued 1-year target prices for Harvard Bioscience's shares. Their HBIO share price forecasts range from $3.00 to $5.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 50.4% from the stock's current price.
View analysts price targets for HBIO
or view top-rated stocks among Wall Street analysts.

How have HBIO shares performed in 2022?

Harvard Bioscience's stock was trading at $7.05 at the beginning of the year. Since then, HBIO shares have decreased by 62.3% and is now trading at $2.66.
View the best growth stocks for 2022 here
.

Are investors shorting Harvard Bioscience?

Harvard Bioscience saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 277,700 shares, an increase of 8.1% from the October 31st total of 256,800 shares. Based on an average daily volume of 107,800 shares, the short-interest ratio is presently 2.6 days. Currently, 0.8% of the shares of the stock are sold short.
View Harvard Bioscience's Short Interest
.

When is Harvard Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our HBIO earnings forecast
.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) issued its earnings results on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.06. The medical instruments supplier had revenue of $29.66 million for the quarter, compared to analysts' expectations of $28.10 million. Harvard Bioscience had a negative net margin of 5.84% and a positive trailing twelve-month return on equity of 4.00%. During the same quarter in the previous year, the business posted $0.01 EPS.

What guidance has Harvard Bioscience issued on next quarter's earnings?

Harvard Bioscience issued an update on its fourth quarter 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $30.00 million-$30.00 million, compared to the consensus revenue estimate of $32.78 million.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by many different institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (4.18%), B. Riley Asset Management LLC (4.12%), AMH Equity Ltd (3.89%), Royce & Associates LP (3.60%), Portolan Capital Management LLC (3.22%) and BlackRock Inc. (2.86%). Insiders that own company stock include Alan I Edrick, Bertrand Loy, James W Green and James W Green.
View institutional ownership trends
.

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $2.66.

How much money does Harvard Bioscience make?

Harvard Bioscience (NASDAQ:HBIO) has a market capitalization of $110.82 million and generates $118.90 million in revenue each year. The medical instruments supplier earns $-290,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does Harvard Bioscience have?

The company employs 475 workers across the globe.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The official website for the company is www.harvardbioscience.com. The medical instruments supplier can be reached via phone at (508) 893-8999, via email at info@harvardbioscience.com, or via fax at 508-429-5732.

This page (NASDAQ:HBIO) was last updated on 12/9/2022 by MarketBeat.com Staff